Ontology highlight
ABSTRACT:
SUBMITTER: Crespi GA
PROVIDER: S-EPMC4549621 | biostudies-literature | 2015
REPOSITORIES: biostudies-literature
Crespi Gabriela A N GA Hermans Stefan J SJ Parker Michael W MW Miles Luke A LA
Scientific reports 20150416
Solanezumab (Eli Lilly) and crenezumab (Genentech) are the leading clinical antibodies targeting Amyloid-β (Aβ) to be tested in multiple Phase III clinical trials for the prevention of Alzheimer's disease in at-risk individuals. Aβ capture by these clinical antibodies is explained here with the first reported mid-region Aβ-anti-Aβ complex crystal structure. Solanezumab accommodates a large Aβ epitope (960 Å(2) buried interface over residues 16 to 26) that forms extensive contacts and hydrogen bo ...[more]